Portfolio - Articles PRA

Understanding the classes: long acting oral opioids
Provincial Reimbursement Advisor 2010;13(1)
Welner S, Rindress D, Tony M

Understanding the classes: tyrosine kinase inhibitors for CML
Provincial Reimbursement Advisor 2009;12(4):46-53.
O'Neil WM, Rindress D, Welner S, Tony M

Understanding the classes: proton pump inhibitors
Provincial Reimbursement Advisor 2009;12(3):56-66.
Welner S, Khoury H, Wagner M, Rindress D

Understanding the classes: statins
Provincial Reimbursement Advisor 2009;12(2)
Wagner M, Rindress D, Welner S

Understanding the classes: atypical antipsychotics - update
Provincial Reimbursement Advisor 2009;12(1)
Wagner M, Rindress D, Welner S

Understanding the classes: triptans for migraines
Provincial Reimbursement Advisor 2008;11(4):41-52.
McCann J, O'Neil B, Rindress D, Welner S

Understanding the classes: drugs for diabetes mellitus
Provincial Reimbursement Advisor 2008;11(3):52-63.
McCann J, Dourdin N, Welner S, Rindress D

Understanding the classes: osteoporosis
Provincial Reimbursement Advisor 2008;11(2):50-7.
Dourdin N, Rindress D, Welner S

Understanding the classes: disease-modifying drugs for multiple sclerosis
Provincial Reimbursement Advisor 2008;11(1):56-63.
Dourdin N, O'Neil B, Rindress D, Welner

Understanding the classes: HIV protease inhibitors
Provincial Reimbursement Advisor 2007;10(4):45-53.
O'Neil B, Welner S, Rindress D

Understanding the Classes: prostaglandin F2-alpha analogues for glaucoma
Provincial Reimbursement Advisor 2007;10(3):48-54.
Levitt R, Welner S, Rindress D

Understanding the classes: Parkinson's Disease
Provincial Reimbursement Advisor 2007;10(2):49-57.
Levitt R, Khoury H, Welner S

Understanding the classes: drugs for attention deficit/hyperactivity disorder
Provincial Reimbursement Advisor 2006;10(1):54-61.
Khoury H, Welner S

Understanding the classes: drugs for rheumatoid arthritis
Provincial Reimbursement Advisor 2006;9(4):47-54.
Khoury H, Rindress D, Welner S

Understanding the classes: angiotensin II receptor blockers for hypertension
Provincial Reimbursement Advisor 2006;9(3):47-54.
Melnyk P, Rindress D, Welner S

Understanding the classes: SSRIs and SNRIs for depression
Provincial Reimbursement Advisor 2006;9(2):45-51.
Melnyk P, Rindress D, Welner S

Understanding the classes: macrolides for systemic bacterial infections
Provincial Reimbursement Advisor 2006;9(1):44-53.
Melnyk P, Welner S, Rindress D

Understanding the classes: drugs for diabetes mellitus
Provincial Reimbursement Advisor 2005;8(4):45-54.
Landry A, Welner S, Rindress D

Understanding the classes: drugs for hepatitis C
Provincial Reimbursement Advisor 2005;8(3):56-65.
Landry A, Welner S, Rindress D

Understanding the classes: drugs for benign prostatic hyperplasia
Provincial Reimbursement Advisor 2005;8(2):55-62.
McLachlin DT, Welner S, Rindress D

Understanding the classes: antiplatelet agents for prevention of cardiovascular events
Provincial Reimbursement Advisor 2005;8(1):51-61.
Landry A, Rindress D

Understanding the classes: serotonin antagonists for cancer therapy-induced emesis
Provincial Reimbursement Advisor 2004;7(4):42-51.
Wagner M, Landry A, Welner S, Rindress D

Understanding the classes: triptans
Provincial Reimbursement Advisor 2004;7(3):45-53.
Landry A, Welner S, Rindress D

Understanding the classes: cyclooxygenase-2 Inhibitors
Provincial Reimbursement Advisor 2004;7(2):45-54.
McLachlin D, Goodz S, Welner S

Understanding the classes: protease inhibitors for HIV infection
Provincial Reimbursement Advisor 2004;7(1):46-53.
Goodz S, Rindress D, Welner S

Understanding the classes: inhaled corticosteroids for asthma and chronic obstructive
pulmonary disease
Provincial Reimbursement Advisor 2003;6(4):47-59.
Sidiropoulos E, Goodz S, Welner S

Understanding the classes: statins
Provincial Reimbursement Advisor 2003;6(3):52-60.
Goodz S, Rindress D, Welner S

Understanding the classes: bisphosphonates
Provincial Reimbursement Advisor 2003;6(2):48-57.
Andrew P, Sidiropoulos E, Welner S

Understanding the classes: biological response modifiers for rheumatoid arthritis
Provincial Reimbursement Advisor 2003;6(1):53-61.
Goodz S, Rindress D, Welner S

Understanding the classes: fluoroquinolones
Provincial Reimbursement Advisor 2002;5(4):48-63.
Forrest S, Sidiropoulos E, Welner S

Understanding the classes: proton pump inhibitors
Provincial Reimbursement Advisor 2002;5(3):44-55.
Sidiropoulos E, Rindress D, Welner S

Understanding the classes: angiotensin II receptor blockers
Provincial Reimbursement Advisor 2002;5(2):49-55.
Andrew P, Goetghebeur MM, Rindress D

Understanding the classes: atypical antipsychotics
Provincial Reimbursement Advisor 2002;5(1):45-53.
Sidiropoulos E, Welner S, Rindress D

Understanding the classes: immunomodulators for multiple sclerosis
Provincial Reimbursement Advisor 2001;4(4):45-52.
Andrew P, Sidiropoulos E, Welner S, Rindress D

Understanding the classes: the statins
Provincial Reimbursement Advisor 2001;4(3):46-51.
Sidiropoulos E, Welner S, Rindress D

Understanding the classes: glitazones for type 2 diabetes
Provincial Reimbursement Advisor 2001;4(2):44-9.
Sidiropoulos E, Welner S

Understanding the classes: cholinesterase inhibitors
Provincial Reimbursement Advisor 2001;4(1):38-44.
Sidiropoulos E, Goetghebeur MM, Rindress D

Understanding the classes: bisphosphonates
Provincial Reimbursement Advisor 2000;3(4):34-40.
Welner S

Understanding the classes: COX-2 Inhibitors
Provincial Reimbursement Advisor 2000;3(3):50-55.
Welner S, McTavish A

Understanding the classes: triptans
Provincial Reimbursement Advisor 2000;3(2):35-41.
Goetghebeur MM, Rindress D

Understanding the classes: leukotriene agents
Provincial Reimbursement Advisor 2000;3(1):36-41.
Welner S, Rindress D

Understanding the classes: angiotensin converting enzyme inhibitors
Provincial Reimbursement Advisor 1999;2(4):30-8.
Goetghebeur MM, Rindress D

Understanding the classes: proton pump inhibitors
Provincial Reimbursement Advisor 1999;2(3):36-42.
Goetghebeur MM, McTavish A, Rindress D

Haut de page